Clinical Trial Update: A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants With Inhibitors [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating emicizumab prophylaxis versus no prophylaxis in people with Hemophilia A and inhibitors; study completed and results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• Emicizumab (emicizumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Hemophilia A | Phase 3 | Status: COMPLETED | Results posted: 2017-11-24